Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1.-99. (Cancelled)

100. (Currently Amended) A composition which comprises:

a) a conjugate of (i) ~~a GM2 or a GD2 ganglioside derivative which derivative comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a ganglioside, which ganglioside (1) is a GM2 or GD2 ganglioside and (2) comprises an unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) ~~a derivative of~~ Keyhole Limpet Hemocyanin, wherein the GM2 or GD2 ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21~~, a saponin derivable from the bark of a Quillaja saponaria Molina tree~~; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GM2 or GD2 ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of ~~the saponin~~ QS-21 is an amount of between about 10 µg and about 200 µg, ~~and~~ the GM2 or GD2:Keyhole Limpet Hemocyanin ~~derivative~~ molar ratio is from 200:1 to 1400:1, and the relative amounts of such conjugate and ~~such saponin being~~ QS-21 is effective to stimulate or enhance production in a subject of an antibody to GM2 and GD2, ~~whichever~~ the ganglioside, ~~is present as a~~ the derivative of which is present in the conjugate.[[,]]

~~wherein in the conjugate the ganglioside derivative is covalently bound to the derivative of Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH_2 group.~~

101.-105. (Cancelled)

106. (Previously Presented) The composition of claim 100 wherein the ganglioside derivative is a GM2 ganglioside derivative and wherein the amount of

the conjugated GM2 ganglioside derivative is an amount of about 30 µg.

107. (Previously Presented) The composition of claim 100 wherein the ganglioside derivative is a GD2 ganglioside derivative and wherein the amount of the conjugated GD2 ganglioside derivative is an amount of about 70 µg.

108. (Cancelled)

109. (Currently Amended) The composition of claim 100 wherein the amount of QS-21 ~~the saponin~~ is about 50 ~~100~~ µg.

110. (Currently Amended) The composition of claim 100 wherein the amount of QS-21 ~~the saponin~~ is about 200 µg.

111. (Cancelled)

112. (Currently Amended) The composition of claim 100 which comprises:

a) a conjugate of (i) ~~a GM2 or a GD2 ganglioside derivative which derivative comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a ganglioside, which ganglioside (1) is a GM2 or GD2 ganglioside and (2) comprises an

unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) ~~a derivative of~~ Keyhole Limpet Hemocyanin, wherein the GM2 or GD2 ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21~~, a saponin derivable from the bark of a Quillaja saponaria Molina tree,~~; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GM2 or GD2 ganglioside derivative is ~~present in~~ an amount between about 1 μg and about 200 μg, the amount of ~~the saponin~~ QS-21 is about 100 μg ~~and~~ the GM2 or GD2:Keyhole Limpet Hemocyanin ~~derivative~~ molar ratio is from 200:1 to 1400:1, ~~where~~ and the relative amounts ~~amount~~ of such conjugate and ~~such saponin~~ QS-21 is effective to stimulate or enhance production in a subject of an antibody to GM2 and GD2, ~~whichever~~ the ganglioside, ~~is present as a~~ the derivative of which is present in the conjugate.[[;]]

~~and wherein in the conjugate the ganglioside derivative is covalently bound to the derivative~~

~~of Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH_2 group.~~

113. (Previously Presented) A method of treating a subject afflicted with melanoma which comprises administering to said subject an amount of the composition of claim 112 effective to stimulate or enhance production of an antibody directed to at least one of GM2 and GD2 and to thereby treat said melanoma in said subject.

114. (Currently Amended) A method of stimulating or enhancing production of an antibody directed to GM2 or GD2 in a subject which comprises administering to the subject an effective amount of a composition which comprises:

a) a conjugate of (i) ~~a GM2 or a GD2 ganglioside derivative which derivative comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a ganglioside, which ganglioside (1) is a GM2 or GD2 ganglioside and (2) comprises an unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine

base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) ~~a derivative of~~ Keyhole Limpet Hemocyanin, wherein the GM2 or GD2 ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21~~, a saponin derivable from the bark of a Quillaja saponaria Molina tree~~; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GM2 or GD2 ganglioside derivative is an amount between ~~abut~~ about 1 μg and ~~abut~~ about 200 μg, the amount of ~~the saponin~~ QS-21 is an amount between about 10 μg and about 200 μg, ~~and~~ the GM2 or GD2:Keyhole Limpet Hemocyanin ~~derivative~~ molar ratio is from 200:1 to 1400:1, and the relative amounts of such conjugate and ~~such saponin being~~ QS-21 is effective to stimulate or enhance production in a subject to an antibody to GM2 and GD2, ~~whichever~~ the ganglioside, ~~is present as a~~ the derivative of which is present in the conjugate.[[,]]

~~wherein in the conjugate the ganglioside derivative is covalently bound to the derivative of Keyhole Limpet Hemocyanin through a C-4 carbon of the altered sphingosine base of the~~

~~altered ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin, wherein the C-4 carbon is present in a CH2 group, so as to thereby stimulate or enhance production of the antibody to GM2 and GD2 in the subject, whichever is present as a derivative in the conjugate.~~

115. (Currently Amended) A method of treating a human subject having cancer which comprises administering to the subject an effective cancer-treating amount of a composition which comprises:

a) a conjugate of (i) ~~a GM2 or a GD2 ganglioside derivative which derivative comprises an unaltered oligosaccharide part and an altered ceramide portion comprising an altered sphingosine base~~ a derivative of a ganglioside, which ganglioside (1) is a GM2 or GD2 ganglioside and (2) comprises an unaltered sphingosine base, wherein the derivative differs from the ganglioside solely by having an altered sphingosine base which retains only C1 through C4 from the unaltered sphingosine base of the ganglioside, and (ii) ~~a derivative of~~ Keyhole Limpet Hemocyanin, wherein the GM2 or GD2 ganglioside derivative is covalently bound to Keyhole Limpet Hemocyanin by a stable amine bond between the C-4 carbon of the altered sphingosine

base and a nitrogen of an ε-aminolysyl group of Keyhole Limpet Hemocyanin;

b) QS-21~~, a saponin derivable from the bark of a Quillaja saponaria Molina tree~~; and

c) a pharmaceutically acceptable carrier;

wherein the amount of the conjugated GM2 or GD2 ganglioside derivative is an amount between about 1 µg and about 200 µg, the amount of ~~the saponin~~ QS-21 is an amount of between ~~abut~~ about 10 µg and about 200 µg, ~~and~~ the GM2 or GD2:Keyhole Limpet Hemocyanin ~~derivative~~ molar ratio is from 200:1 to 1400:1, and the relative amounts of such conjugate and ~~such saponin being~~ QS-21 is effective to stimulate or enhance production in a subject of an antibody to GM2 and GD2, ~~whichever~~ the ganglioside, the ~~is present as a~~ derivative of which is present in the conjugate.[[;]]

~~wherein in the conjugate the ganglioside derivative is covalently bound to the derivative of Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to an ε-aminolysyl group of Keyhole Limpet Hemocyanin, and wherein the C-4 carbon is present in a CD2 group, so as to thereby stimulate or enhance production of the antibody to GM2 and GD2 in the subject, whichever is present as a derivative in the conujugate.~~

116. (Previously Presented) The method of claim 115, wherein the cancer is of epithelial origin.

117. (Previously Presented) The method of claim 115, wherein the cancer is of neuroectodermal origin.

118. (Currently Amended) The method of claim 117, wherein the cancer of neuroectodermal origin is ~~a~~ melanoma.

119. (Previously Presented) The method of claim 114 or 115, wherein the administering is effected at two or more sites.

120. (Previously Presented) The method of claim 119, wherein the administering is effected at three sites.

121. (Previously Presented) The method of claim 114 or 115, wherein the composition is administered subcutaneously to said subject.

122. (Previously Presented) The method of claim 121, wherein the composition is administered to said subject at two-week intervals.

123. (Previously Presented) The method of claim 121, wherein the composition is initially administered to said subject at weekly intervals.

124. (Currently Amended) The method of claim 114 or

115, wherein the composition to be administered is prepared prior to administration to the subject by mixing the conjugate and QS-21 ~~the saponin~~.

125. (Currently Amended) The method of claim 124, wherein the conjugate and QS-21 ~~the saponin~~ are mixed on the day of administration to the subject.

126. (Cancelled)